Merck Plans to Move Global Headquarters within New Jersey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck Plans to Move Global Headquarters within New Jersey


ePT--the Electronic Newsletter of Pharmaceutical Technology

Merck & Co. has announced plans to relocate the company’s global headquarters within the state of New Jersey (NJ), with the transition expected to begin in 2014 and be completed by mid-2015, according to an Oct. 9, 2012, press release. The company will close its current headquarters building in Whitehouse Station, NJ, where it has been since 1992, and move the headquarters less than 30 miles to the northeast to its existing property in Summit, NJ. The Summit facility currently houses 1800 people in research, manufacturing, animal health, and consumer care operations. About 2000 employees and contractors currently working in Whitehouse Station will move to the Summit location or to other nearby facilities such as those in Branchburg, NJ and Cokesbury, NJ.

The headquarters relocation is part of the company's ongoing program to consolidate its global real estate footprint and lower its annual operating expenses. The Summit location was selected because it is a multiuse site with excess workspace capacity and is near major transportation hubs and urban centers, said the company in the press release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here